由买买提看人间百态

boards

本页内容为未名空间相应帖子的节选和存档,一周内的贴子最多显示50字,超过一周显示500字 访问原贴
_pennystock版 - 转载<– I Think BIEL Shares are Headed A Lot Higher >
相关主题
低价的FDA Decision Calendar (9月份,10月份,11月份,12月份biel
FDA 510(K) estimate respond dayc and biel
BIELBIEL 是不是一个BUY?
PVCT & PWRMc and biel
09/17周四看点建仓快完成,不盯盘了
BIEL有信息含量的帖子汇总BIEL
bielbiel
biel还有人陪我留着cctr么?
相关话题的讨论汇总
话题: company话题: biel话题: latin话题: canadian
1 (共1页)
e****1
发帖数: 207
1
BioElectronics Management Team – Taking Care of Business – What to Expect
Over the Short Term – I Think BIEL Shares are Headed A Lot Higher
by Joe on March 27, 2010
BioElectronics Management Team – Taking Care of Business – What to Expect
Over the Short Term – I Think BIEL Shares are Headed A Lot Higher
We have been very impressed over the past couple of months as we have
watched the BioElectronics management team take care of the important tasks
that need to be accomplished in order to ensure success and believe there is
reason for shareholder optimism going forward.
Below, I have outlined some of these accomplishments. Additionally, I have
listed some of the things investors should expect to see over the short term
, including production of Q4:09 and year end financial results, release of
the Company’s full year 2009 audit, SEC filing to become a fully reporting
company, a formal response to the FDA relative to the pending 510K
applications, release of additional information on the status of the Latin
American and Canadian DRTV launches and information relative to the
regulatory status and marketing efforts in Japan and China. We certainly
believe it is going to be a very exciting upcoming 30 day period for
BioElectronics and its shareholders. Watch closely as this management team
continues to accelerate on its execution.
2008 Audit and Q1:09 through Q3:09 Financial Review – Several weeks ago,
the Company announced the results of the 2008 audit and the completion of a
nine-month financial review. This was a substantial undertaking as BIEL has
a small management team. To accomplish the audit, several senior people had
to be pulled off of other projects in order to assemble the documentation
required by the auditor. This was a huge amount of work, but the Company
completed it in relatively short order.
Latin American Launch – The Latin American Direct Response Television (DRTV
) campaign kicked off a few weeks ago and has been a major success for the
Company. In the DRTV market, one of the most important operational dynamics
is the media efficiency ratio, which outlines the amount of revenue gain for
each dollar of advertising spent. A four to one ratio is considered
excellent. The test of the Latin American market resulted in a five to one
ratio. As a result, the distributor will be significantly increasing the
advertising spend. If the general market behaves in a manner similar to the
test, this should be a major revenue generator for BioElectronics. What we
believe is highly significant relative to the Latin America launch is that
it is the first time a mass market was presented with the product offering
and it appears the mass market was excited about the offering. Hopefully,
this excitement will translate to other markets.
Canada DRTV Initiative – Several months ago, BioElectronics completed its
television spots oriented for the Canadian market. The distributor and the
Canadian government regulator requested that several changes be made to the
commercials. These changes have now been completed, and the official tests
of the market are scheduled to occur over the next few days. While a very
small test ($10,000) was initially planned, the decision has now been made
to undergo a much larger test, likely in the area of $25,000 of media
spending. This is a rather significant amount for a Canadian test, which we
believe shows the distributor’s level of confidence in its success. The
Canadian market isn’t particularly large relative to some of the other
markets BioElectronics will target, but it will nevertheless give the
Company significant experience within the English speaking world.
Japan and China – As the Company has previously announced, major
initiatives are underway in these two major Asian markets. It is expected
that regulatory clearance will be relatively easy within both countries.
Product Quality – As we have written about previously, we are very
impressed with the product improvements that have recently been completed.
The new elastic “wraps” that attach the ActiPatch unit to the body are a
significant improvement. It is made out of a strong, flexible material that
has a mesh design that allows for air circulation. Simply put, it is a huge
improvement in overall product quality.
New Product Designs – The management team at BioElectronics has not spent a
lot of time discussing new product initiatives and designs. We believe
there are two that are very important. First, is the back pain belt that the
Company mentioned in a press release a couple of months ago. This back pain
specific product is based on a very high quality design that will allow a
user to easily locate the control unit directly over the site of back pain.
We do not believe there is anything like it currently available on the
market and believe it could be a major revenue producer within multi-billion
dollar back pain relief segment. Additionally, on the drawing board for the
past several months, has been a specific foot pain product where the active
technology is integrated directly into a miniaturized version of the
product that can be installed within a shoe. While this product is still on
the drawing board and will likely not be available until next year, we
believe it shows the flexibility of the Company’s technology.
Revenue Generation – The Q4 revenue numbers have not yet been released, but
investors should expect some impressive results as large orders were gained
during the quarter from Japan, Turkey, Korea and several European markets.
Balance Sheet – It is usually difficult for small companies that trade on
the pink sheets to raise capital. This has not been the case relative to
BioElectronics as many long-time loyal shareholders have provided
substantial financial support to the Company. This has allowed
BioElectronics to pay off nearly all of its trade payables and long-term
debt. BIEL’s balance sheet is now relatively strong, with the only long-
term debt still outstanding owed to longtime friendly shareholders.
What to Expect over the Short Term (Next 30 Days)
Release of the Year End Numbers – Expect to BioElectronics to release Q4
numbers over the next two weeks. While the actual release date has not yet
been set, investors will likely see the numbers before April 15th.
The Audit of Full Year 2009 – Corresponding with the release of the year-
end numbers, will likely be the release of the audit results for the full
year 2009. This should be available by April 15th, but I would remind
investors that the actual release of the audit results depends on the
auditor, not corporate management.
Fully Reporting Status – While it is important for the Company to release
the year end numbers and have the full year are audit available, what is
even more important is filing all of this information in the proper format
with the Securities and Exchange Commission. Management has been hard at
work for preparing such documentation. Investors should expect the Company
to file a Form 10-K with the Securities and Exchange Commission by the end
of April. This will be a major event for the Company as it will open up a
host of alternatives and greatly increase the Company’s flexibility
relative to several issues.
Additional FDA Response Filing – Look for BioElectronics to file an
additional response relative to its 510K filings over the short term. The
Company has hired a highly qualified FDA consultant to work with it on the
510K responses to FDA. I believe it is an understatement to say that
BioElectronics’s management team is excited about filing this response and
the results they expect. Stay tuned for more information relative to this
extremely important event.
Becoming fully reporting with the SEC will allow the Company to execute a
strategy, if it chooses, to move the trading of its shares to the OTC market
. Additionally, becoming fully reporting should take care of lingering
issues at TD AmeriTrade and Scottrade, both of which periodically do not
allow for the purchase of BIEL shares. An additional likely result will be
the removal of the “DTC Chill” that limits the ability of brokerage firms
to clear BIEL certificates electronically.
While issues of where the stock trades, which brokers trade it and
electronic clearance of stock certificates are certainly important relative
to becoming fully reporting, an even more important overall issue is the
significant amount of credibility this management team and Company will gain
through the process of becoming fully reporting. We believe this added
credibility alone is likely worth an additional 25% increase in BIEL share
valuation.
Additional Information on Latin America and Canadian DRTV Campaigns – BIEL
has been marketing its products to the public for several years. While
marketing has been ongoing, such efforts have been directed at only two
isolated pockets of the total market. The DRTV campaigns in Latin America
and Canada will represent the first true mass market attempt ever made by
the Company. We believe this is a marketing case of “Will the dogs eat the
dog food?” Thus far, we have seen indications of strong market acceptance
in Latin America. If the Company gets a similar response out of Canada, we
should have some basis to say that such results are transferable to other
markets. We believe additional information on the Latin America and Canadian
DRTV campaigns could be the tipping point that could drive investors to
once again place meaningful bets on the bright future of this Company.
Information on the Status of Japanese and Chinese Markets – As has been
publicly announced, BioElectronics has major initiatives set for Japan and
China. Investors should be watching closely for news on the regulatory
status and marketing initiatives relative to both of these huge potential
markets for the ActiPatch and Allay brands.
Summary – It’s great to see the BIEL team taking care of business. With a
new response for the 510K’s ready to go into the FDA, strong rev growth,
completion of the audit, announcement of the year end numbers, an important
10K SEC filing with the SEC, achievement of fully reporting status, a
successful Latin American launch and a pending Canadian launch, these shares
are likely going a lot higher over the short term. Having watched this
Company for more than two years now, I am impressed with all the positive
things that are happening.
Joe Noel
n****e
发帖数: 1677
2
先顶一下,等晚上再研究。

Expect
Expect
tasks
is

【在 e****1 的大作中提到】
: BioElectronics Management Team – Taking Care of Business – What to Expect
: Over the Short Term – I Think BIEL Shares are Headed A Lot Higher
: by Joe on March 27, 2010
: BioElectronics Management Team – Taking Care of Business – What to Expect
: Over the Short Term – I Think BIEL Shares are Headed A Lot Higher
: We have been very impressed over the past couple of months as we have
: watched the BioElectronics management team take care of the important tasks
: that need to be accomplished in order to ensure success and believe there is
: reason for shareholder optimism going forward.
: Below, I have outlined some of these accomplishments. Additionally, I have

z*******n
发帖数: 49
3
谢谢

Expect
Expect
tasks
is

【在 e****1 的大作中提到】
: BioElectronics Management Team – Taking Care of Business – What to Expect
: Over the Short Term – I Think BIEL Shares are Headed A Lot Higher
: by Joe on March 27, 2010
: BioElectronics Management Team – Taking Care of Business – What to Expect
: Over the Short Term – I Think BIEL Shares are Headed A Lot Higher
: We have been very impressed over the past couple of months as we have
: watched the BioElectronics management team take care of the important tasks
: that need to be accomplished in order to ensure success and believe there is
: reason for shareholder optimism going forward.
: Below, I have outlined some of these accomplishments. Additionally, I have

e****1
发帖数: 207
4
对这股要有点耐心,现在觉得它是万事具备,只欠MM.
1 (共1页)
相关主题
还有人陪我留着cctr么?09/17周四看点
呵呵呵,买了1000大家都不知道的股BIEL有信息含量的帖子汇总
BIEL!biel
还有人记得biel么?biel
低价的FDA Decision Calendar (9月份,10月份,11月份,12月份biel
FDA 510(K) estimate respond dayc and biel
BIELBIEL 是不是一个BUY?
PVCT & PWRMc and biel
相关话题的讨论汇总
话题: company话题: biel话题: latin话题: canadian